Latest 10-Q quarterly reports

Kalaris Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses and a strong reliance on future financing, while advancing its lead drug candidate TH103.

Hemab Therapeutics Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in R&D, progress in clinical trials for sutacimig and HMB-002, and a substantial cash position post-IPO.

Helios Technologies announces robust Q2 2026 results with significant increases in net sales, gross profit, and operating income, driven by strong performance in both Hydraulics and Electronics segments.

Flanigans Enterprises, Inc. announced a significant increase in revenue and net income for the third quarter ended June 27, 2026, driven by price increases and higher customer traffic.

Purple Innovation, Inc. reported a net loss of $3.2 million for Q2 2026, with revenues down 6.5% year-over-year, while acknowledging substantial doubt about its ability to continue as a going concern.

LataMed AI Corp. reported no revenue and significant operating losses for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.

Golden Growers Cooperative filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in corn revenue and net income, while also detailing progress on its approved Plan of Liquidation and Dissolution.

Momentus Inc. filed its Q2 2026 10-Q, detailing a significant increase in revenue and substantial capital raised, but also reporting a widening net loss and increased operating expenses.

Ambiq Micro reports a substantial 89.7% increase in net sales for the quarter ended June 30, 2026, driven by new product launches and customer adoption, while continuing to invest heavily in R&D.

PLAYSTUDIOS, Inc. announced its Q2 2026 financial results, showing a 7.3% decrease in net revenue and a significant widening of its net loss compared to the prior year period.

Independence Power Holdings, Inc. filed its Q2 2026 Form 10-Q, detailing significant net losses and no current revenue, while highlighting progress in asset management contracts and a secured note receivable.

Sentient Brands Holdings Inc. reported increased revenue for Q2 2026, but continued to incur net losses and faces substantial doubt regarding its ability to continue as a going concern.

Osprey Bitcoin Trust experienced a significant decrease in net assets for Q2 2026, primarily due to a substantial unrealized loss on its Bitcoin holdings.

Magnolia Bancorp, Inc. reported a net loss for the six months ended June 30, 2026, with total assets and deposits decreasing, though net interest income saw a modest increase.

Equator Beverage Company announced a significant increase in revenue and net income for the second quarter of 2026, driven by operational efficiencies and a substantial tax benefit.

BlueOne Technologies, Inc. filed its Q2 2026 10-Q, revealing a significant decrease in revenue and continued operating losses, raising substantial doubt about its ability to continue as a going concern.

Uwharrie Capital Corp announced a significant increase in net income for the second quarter of 2026, driven by robust deposit growth and a notable gain from a Visa stock exchange.

Chain Bridge Bancorp, Inc. (CBNA) announced a significant increase in net income and assets for the second quarter of 2026, driven by strong net interest income and noninterest income growth.

AsiaFIN Holdings Corp. announced a substantial 50.5% increase in revenue for the second quarter of 2026, returning to profitability after a period of net loss.

Vor Biopharma Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical trials for telitacicept and significant net losses, while highlighting cash runway into early 2029.

Microbot Medical Inc. announced its Q2 2026 financial results, showing initial revenues from its LIBERTY Endovascular Robotic System following its full market release.

United-Guardian, Inc. announced a 10% increase in net sales for Q2 2026 and a 12% increase for the first half, driven by pharmaceutical and cosmetic ingredient sales, alongside improved net income.

Future Vision II Acquisition Corp. reports on its financial status for the quarter ended June 30, 2026, highlighting ongoing efforts to secure a business combination before its extended deadline, with a significant risk of liquidation if unsuccessful.

TON Strategy Company's Q2 2026 results show a significant surge in revenue from GRAM staking, alongside a substantial unrealized gain on digital assets, though operating expenses and legal matters persist.

Mereo BioPharma Group plc filed its Q2 2026 10-Q, detailing continued net losses, reduced R&D spending, and a significant new licensing agreement for alvelestat.

Energy Focus, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting significant revenue increases but also continued net losses and a substantial accumulated deficit.

Adagio Medical Holdings, Inc. reported continued net losses and significant cash burn in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, despite advancing its vCLAS Ventricular Ablation System through clinical trials and regulatory submissions.

Imunon, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Barnwell Industries, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a reduced net loss and progress in divesting non-core assets.

Theriva Biologics, Inc. reported continued operating losses and substantial accumulated deficit in its Q2 2026 10-Q filing, raising significant doubts about its ability to continue as a going concern, despite positive clinical trial updates.